阿尔茨海默氏症疾病的频谱
J S Novotny1, M Čarná1, I Lyburn2,3
1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
medRxiv : the preprint server for health sciences
|December 3, 2025
概括
使用脑部扫描诊断阿尔茨海默病的诊断是复杂的. 扩大状交叉体 (ChP) 和其他大脑体积变化不能可靠地预测AD,表明不同的疾病亚型.
科学领域:
- 神经学 神经学
- 神经成像是一种神经成像.
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 海马体 (H) 和下叶 (IPL) 缩是阿尔茨海默病 (AD) 诊断的标准.
- 在阿尔茨海默氏症中,扩大胆膜 (ChP) 的诊断作用仍然不确定.
- 研究AD的体积变化对于理解疾病异质性至关重要.
研究的目的:
- 为了研究在阿尔茨海默氏症 (AD) 中扩大胆膜 (ChP) 的预测价值.
- 检查基于MRI的体积大脑变化对预测AD的贡献.
- 分析AD神经成像计划 (ADNI) 队列的体积变化.
主要方法:
- 在AD神经成像计划 (ADNI) 队列 (N=872) 中利用了MRI体积.
- 评估了海马体 (H),胆脉 (ChP) 和下叶 (IPL) 的个体和综合体积变化.
- 与AD诊断和纵向变化相关的体积检测结果.
主要成果:
- 没有单个体积大脑变化或组合可靠地预测AD诊断.
- 很大一部分AD患者 (45%) 没有表现出大脑体积变化,即使是纵向变化.
- 观察到的H,ChP或IPL体积变化仅发生在AD患者的一小部分 (19%,12%,5%).
结论:
- 粉样蛋白-β酸只在一小部分粉样蛋白PET-CT阳性AD患者中导致大脑缩.
- 在阿尔茨海默氏症中,大脑体积表型多样化,这表明在阿尔茨海默氏症谱中存在独特的疾病实体.
- 研究结果支持AD异质性的概念,类似于其他神经退行性蛋白质病变.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
Dementia
487
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
487
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
440
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
440
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K


